|
1
|
Kamai T, Shirataki H, Nakanishi K, Furuya
N, Kambara T, Abe H, Oyama T and Yoshida K: Increased Rac1 activity
and Pak1 overexpression are associated with lymphovascular invasion
and lymph node metastasis of upper urinary tract cancer. BMC
Cancer. 10:1642010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hall MC, Womack S, Sagalowsky AI, Carmody
T, Erickstad MD and Roehrborn CG: Prognostic factors, recurrence,
and survival in transitional cell carcinoma of the upper urinary
tract: A 30-year experience in 252 patients. Urology. 52:594–601.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tanaka N, Kikuchi E, Kanao K, Matsumoto K,
Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, Shirotake S, et
al: Patient characteristics and outcomes in metastatic upper tract
urothelial carcinoma after radical nephroureterectomy: The
experience of Japanese multi-institutions. BJU Int. 112:E28–E34.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kikuchi E, Margulis V, Karakiewicz PI,
Roscigno M, Mikami S, Lotan Y, Remzi M, Bolenz C, Langner C, Weizer
A, et al: Lymphovascular invasion predicts clinical outcomes in
patients with node-negative upper tract urothelial carcinoma. J
Clin Oncol. 27:612–618. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kikuchi E, Horiguchi Y, Nakashima J,
Hatakeyama N, Matsumoto M, Nishiyama T and Murai M: Lymphovascular
invasion independently predicts increased disease specific survival
in patients with transitional cell carcinoma of the upper urinary
tract. J Urol. 174:2120–2124. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ozsahin M, Zouhair A, Villà S, Storme G,
Chauvet B, Taussky D, Gouders D, Ries G, Bontemps P, Coucke PA and
Mirimanoff RO: Prognostic factors in urothelial renal pelvis and
ureter tumours: A multicentre Rare Cancer Network study. Eur J
Cancer. 35:738–743. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fujita K, Inamoto T, Yamamoto Y, Tanigawa
G, Nakayama M, Mori N, Tsujihata M, Azuma H, Nonomura N and Uemura
M: Role of adjuvant chemotherapy for lymph node-positive upper
tract urothelial carcinoma and the prognostic significance of
C-reactive protein: A multi-institutional, retrospective study. Int
J Urol. 22:1006–1012. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim HS, Lee JS, Jeong CW, Kwak C, Kim HH
and Ku JH: Adjuvant chemotherapy for locally advanced upper tract
urothelial carcinoma: Updated results of the Seoul National
University Hospital experience. Int Braz J Urol. 41:1067–1079.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kaag MG, O'Malley RL, O'Malley P, Godoy G,
Chen M, Smaldone MC, Hrebinko RL, Raman JD, Bochner B, Dalbagni G,
et al: Changes in renal function following nephroureterectomy may
affect the use of perioperative chemotherapy. Eur Urol. 58:581–587.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lane BR, Smith AK, Larson BT, Gong MC,
Campbell SC, Raghavan D, Dreicer R, Hansel DE and Stephenson AJ:
Chronic kidney disease after nephroureterectomy for upper tract
urothelial carcinoma and implications for the administration of
perioperative chemotherapy. Cancer. 116:2967–2973. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ho DH, Pazdur R, Covington W, Brown N, Huo
YY, Lassere Y and Kuritani J: Comparison of 5-fluorouracil
pharmacokinetics in patients receiving continuous 5-fluorouracil
infusion and oral uracil plus
N1-(2′-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res.
4:2085–2088. 1998.PubMed/NCBI
|
|
12
|
Borner MM, Schoffski P, de Wit R,
Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born
K, Wanders J, et al: Patient preference and pharmacokinetics of
oral modulated UFT versus intravenous fluorouracil and leucovorin:
A randomised crossover trial in advanced colorectal cancer. Eur J
Cancer. 38:349–358. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hamada C, Tanaka F, Ohta M, Fujimura S,
Kodama K, Imaizumi M and Wada H: Meta-analysis of postoperative
adjuvant chemotherapy with tegafur-uracil in non-small-cell lung
cancer. J Clin Oncol. 23:4999–5006. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hamada C, Tsuboi M, Ohta M, Fujimura S,
Kodama K, Imaizumi M and Wada H: Effect of postoperative adjuvant
chemotherapy with tegafur-uracil on survival in patients with stage
IA non-small cell lung cancer: An exploratory analysis from a
meta-analysis of six randomized controlled trials. J Thorac Oncol.
4:1511–1516. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kato T, Ohashi Y, Nakazato H, Koike A,
Saji S, Suzuki H, Takagi H, Nimura Y, Hasumi A, Baba S, et al:
Efficacy of oral UFT as adjuvant chemotherapy to curative resection
of colorectal cancer: Multicenter prospective randomized trial.
Langenbecks Arch Surg. 386:575–581. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Akasu T, Moriya Y, Ohashi Y, Yoshida S,
Shirao K and Kodaira S; National Surgical Adjuvant Study of
Colorectal Cancer, : Adjuvant chemotherapy with uracil-tegafur for
pathological stage III rectal cancer after mesorectal excision with
selective lateral pelvic lymphadenectomy: A multicenter randomized
controlled trial. Jpn J Clin Oncol. 36:237–244. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sakamoto J, Hamada C, Yoshida S, Kodaira
S, Yasutomi M, Kato T, Oba K, Nakazato H, Saji S and Ohashi Y: An
individual patient data meta-analysis of adjuvant therapy with
uracil-tegafur (UFT) in patients with curatively resected rectal
cancer. Br J Cancer. 96:1170–1177. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Maring JG, Groen HJ, Wachters FM, Uges DR
and de Vries EG: Genetic factors influencing pyrimidine-antagonist
chemotherapy. Pharmacogenomics J. 5:226–243. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mizutani Y, Wada H, Fukushima M, Yoshida
O, Nakanishi H, Li YN and Miki T: Prognostic significance of
orotate phosphoribosyltransferase activity in bladder carcinoma.
Cancer. 100:723–731. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mizutani Y, Wada H, Fukushima M, Yoshida
O, Ukimura O, Kawauchi A and Miki T: The significance of
dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer.
Eur J Cancer. 37:569–575. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ide H, Kikuchi E, Hasegawa M, Kozakai N,
Kosaka T, Miyajima A and Oya M: Prognostic significance of
5-fluorouracil metabolism-relating enzymes and enhanced
chemosensitivity to 5-fluorouracil by 5-chloro
2,4-dihydroxy-pyridine in urothelial carcinoma. BMC Cancer.
12:4202012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mizutani Y, Wada H, Ogawa O, Yoshida O,
Fukushima M, Nonomura N and Miki T: Prognostic significance of
thymidylate synthase activity in bladder carcinoma. Cancer.
92:510–518. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM classification of malignant tumours. Wiley-Blackwell. (New
Jersey). 2009.
|
|
24
|
Kimura M, Imamura F, Inoue T, Nishino K,
Uchida J, Kumagai T, Okami J, Higasiyama M and Kamoshida S: Protein
and mRNA expression of folic acid-associated enzymes as biomarkers
for the cytotoxicity of the thymidylate synthase-targeted drugs,
pemetrexed and S-1, in non-small cell lung cancer. Mol Clin Oncol.
7:15–23. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ichikawa W, Terashima M, Ochiai A, Kitada
K, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H and Sasako
M: Impact of insulin-like growth factor-1 receptor and amphiregulin
expression on survival in patients with stage II/III gastric cancer
enrolled in the adjuvant chemotherapy trial of S-1 for gastric
cancer. Gastric Cancer. 20:263–273. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Abe T, Kitamura H, Obara W, Matsumura N,
Tsukamoto T, Fujioka T, Hara I, Murai S, Shinohara N and Nonomura
K: Outcome of metastasectomy for urothelial carcinoma: A
multi-institutional retrospective study in Japan. J Urol.
191:932–936. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tanji N, Ozawa A, Miura N, Yanagihara Y,
Sasaki T, Nishida T, Kikugawa T, Ikeda T, Ochi T, Shimamoto K, et
al: Long-term results of combined chemotherapy with gemcitabine and
cisplatin for metastatic urothelial carcinomas. Int J Clin Oncol.
15:369–375. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kubota Y, Noguchi S and Hosaka M: UFT in
bladder cancer. Oncology (Williston Park). 13 (Suppl 3):S112–S115.
1999.
|
|
30
|
Kubota Y, Hosaka M, Fukushima S and Kondo
I: Prophylactic oral UFT therapy for superficial bladder cancer.
Cancer. 71:1842–1845. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Harada K, Miyake H, Terakawa T and
Fujisawa M: Significance of uracil/tegafur for preventing
intravesical recurrence of non-muscle invasive urothelial carcinoma
of the bladder. Curr Urol. 6:27–32. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takechi T, Fujioka A, Matsushima E and
Fukushima M: Enhancement of the antitumour activity of
5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase
activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human
tumour cells. Eur J Cancer. 38:1271–1277. 2002. View Article : Google Scholar : PubMed/NCBI
|
